President Biden's time in office has finally expired. But his signature legislative accomplishment—the Inflation Reduction Act—will keep negatively impacting Americans for years to come.

The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both ...

Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, potentially expanding treatment access for patients.